Blind Man’s Sight Partially Restored with ‘Optogenetics’ Gene Therapy

Advertisement Continue reading the main story Supported by Continue reading the main story Matter Scientists Partially Restored a Blind Man’s Sight With New Gene Therapy Using a technique called optogenetics, researchers added light-sensitive proteins to the man’s retina, giving him a blurry view of objects. In an experiment, a 58-year-old volunteer with a genetic form… Read More »

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations

FDA Approves Rybrevant (amivantamab-vmjw) as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations May 21, 2021 (HORSHAM, P.A.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has granted the accelerated approval of Rybrevant (amivantamab-vmjw) for the… Read More »